Table 1.

Pharmacokinetic and pharmacodynamic characteristics of aflibercept [34]

• Formulation: intravitreal injection

• Dose: 2 mg in 0.05 mL

• Dosing: every month for 3 months and then every 2 months

Pharmacokinetics

• Time to peak intraocular concentration: immediately following dose

• Volume of distribution: 4 mL

• Half-life: 4.6 days

Pharmacodynamics

• Targets: VEGFA-D, PIGF

• Effect: prevents VEGF receptor activation and stimulation of the angiogenesis cascade

PIGF placental growth factor, VEGF vascular endothelial growth factor